Sponsored research in collaboration with
PrevenTRON is studying whether an investigational treatment can help protect brain health in adults who show early biological signs of Alzheimer's risk, before symptoms appear.
This is meant as a general guide. The study team confirms eligibility with you directly, at no cost or commitment.
You don't need a family history of Alzheimer's to join. Many people who qualify have none at all. Early risk comes from biological testing, separate from family background.
PrevenTRON is one of several studies open at our participating research sites. Here's what's currently recruiting.
Alzheimer's disease develops gradually, often beginning years before any memory symptoms are noticeable. By the time a diagnosis is made, significant changes may have already taken place in the brain.
This is why a growing part of Alzheimer's research, including PrevenTRON, is focused on identifying early biological risk and studying whether acting sooner can change the course of the disease before symptoms ever appear.
Research also suggests that a meaningful share of dementia risk is tied to factors that can potentially be addressed, which is part of why prevention-focused studies matter alongside lifestyle and public health efforts.
Alzheimer's-related changes in the brain can begin years, sometimes decades, before memory problems appear. PrevenTRON is studying whether treating the earliest biological signs can help protect brain health well before symptoms would otherwise appear.
A protein called amyloid can build up in the brain long before any memory changes are noticeable. Researchers believe this early buildup may be part of what eventually leads to Alzheimer's disease.
The study is testing whether an investigational medication can reduce this early buildup in people who are at biological risk but do not yet have memory symptoms, with the goal of delaying or preventing decline.
Have a question about whether PrevenTRON could be right for you? Call anytime. There's no obligation.
Before a medicine is studied in people, it has already gone through years of laboratory and pre-clinical research.
Safety testing is completed in the lab before human trials begin.
Regulatory authorities like the FDA review the data before a study can proceed.
An independent ethics committee (IRB) approves the study protocol.
Human trials confirm how the treatment behaves in the body under close monitoring.
Studies are carefully structured and conducted under ongoing regulatory oversight.
For many participants, being part of a study like PrevenTRON means contributing to research that may benefit people well beyond their own community.
people living with dementia worldwide today
people projected to be living with dementia by 2050
of dementia cases are caused by Alzheimer's disease specifically
new dementia cases are diagnosed worldwide each year
Figures reflect widely cited estimates from the World Health Organization and Alzheimer's Disease International; global dementia research is ongoing and estimates continue to be refined.
Reaching out doesn't commit you to anything. It's simply a chance to ask questions and find out whether PrevenTRON might be a fit.